Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?

Digestive Diseases and Sciences

Volumn 60, Issue 10, 2015, Pages 2946-2952

  Ooi, Chee Y ^a,b   Pang, Tamara ^a   Leach, Steven T ^a   Katz, Tamarah ^b   Day, Andrew S ^c   Jaffe, Adam ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Biological markers; Cystic fibrosis; Inflammation; Innate immunity

Indexed keywords

BETA DEFENSIN 2; CALGRANULIN; BETA DEFENSIN; BIOLOGICAL MARKER; DEFB4A PROTEIN, HUMAN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FECES ANALYSIS; FEMALE; HUMAN; INNATE IMMUNITY; INTESTINE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION; ADOLESCENT; CHEMISTRY; COHORT ANALYSIS; COMPARATIVE STUDY; ENTERITIS; FECES; HOSPITAL; IMMUNOLOGY; METABOLISM; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROSPECTIVE STUDY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; BETA-DEFENSINS; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYSTIC FIBROSIS; ENTERITIS; FECES; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; IMMUNITY, INNATE; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84942196547     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3842-2     Document Type: Article

References (42)

1. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–1073.
2. Quinton PM. Chloride impermeability in cystic fibrosis. Nature. 1983;301:421–422.
3. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995;269:847–850.
4. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009;119:2613–2622.
5. Brennan S. Innate immune activation and cystic fibrosis. Paediatr Respir Rev. 2008;9:271–280.
6. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med. 2010;2:29ra31.
7. O’Brien S, Mulcahy H, Fenlon H, et al. Intestinal bile acid malabsorption in cystic fibrosis. Gut. 1993;34:1137–1141.
8. Hoen AG, Li J, Moulton LA, et al. Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis. J Pediatr. 2015;167:138–147.
9. Schippa S, Iebba V, et al. CFTR allelic variants relate to shifts in fecal microbiota of cystic fibrosis patients. PLoS ONE. 2013;8:e61176.
10. Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci. 2013;58:2275–2281.
11. Pang T, Leach ST, Katz T, Day AS, Ooi CY. Fecal biomarkers of intestinal health and disease in children. Front Pediatr. 2014;2:6.
12. Bruzzese E, Callegari ML, Raia V, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One. 2014;9:e87796.
13. De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Pathol. 2007;293:G104–G111.
14. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immunity. 2004;72:6040–6049.
15. Pang T, Leach ST, Katz T, Jaffe A, Day AS, Ooi CY. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: A clue to the increased risk of intestinal malignancy in adulthood? J Gastroenterol Hepatol. 2015;30:866–871.
16. Dhaliwal J, Leach S, Katz T, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastr Nutr. 2015;60:521–526.
17. Werlin SL, Benuri-Silbiger I, Kerem E, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastr Nutr. 2010;51:304–308.
18. del Campo R, Garriga M, Pérez-Aragón A, et al. Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. J Cyst Fibros. 2014;13:716–722.
19. Selsted ME, Miller SI, Henschen AH, et al. Enteric defensins: antibiotic peptide components of intestinal host defense. J Cell Biol. 1992;118:929–936.
20. Langhorst J, Junge A, Rueffer A, et al. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104:404–410.
21. Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature. 1997;387:861.
22. Diamond G, Russell JP, Bevins CL. Inducible expression of an antibiotic peptide gene in lipopolysaccharide- challenged tracheal epithelial cells. Proc Natl Acad Sci USA. 1996;93:5156–5160.
23. Stolzenberg ED, Anderson GM, Ackermann MR, Whitlock RH, Zasloff M. Epithelial antibiotic induced in states of disease. Proc Natl Acad Sci USA. 1997;94:8686–8690.
24. Wehkamp J, Fellermann K, Herrlinger KR, et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:745–752.
25. Kim MJ, Lee WY, Choe YH. Expression of TIM-3, Human β-defensin-2, and FOXP3 and correlation with disease activity in pediatric Crohn’s disease with infliximab therapy. Gut Liver. 2014. doi:10.5009/gnl13408.
26. Kapel N, Benahmed N, Morali A, et al. Fecal beta-defensin-2 in children with inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2009;48:117–120.
27. Kolho KL, Sipponen T, Valtonen E, Savilahti E. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29:43–50.
28. Dauletbaev N, Gropp R, Frye M, Loitsch S, Wagner TO, Bargon J. Expression of human beta defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals, and individuals with acute cold. Respiration. 2002;69:46–51.
29. Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest. 1998;102:874–880.
30. Van de Kamer HH, Huinick H, Weyers HA. Rapid method for determination of fat in feces. J Biol Chem. 1949;177:347–351.
31. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut. 1996;39:580–586.
32. Fagerberg UL, Loof L, Merzoug RD, et al. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastr Nutr. 2003;37:468–472.
33. Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999;286:525–528.
34. Claeys S, Van Hoecke H, Holtappels G, et al. Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators. Clin Exp Allergy. 2005;35:467–472.
35. Jenke AC, Zilbauer M, Postberg J, Wirth S. Human β-defensin 2 expression in ELBW infants with severe necrotizing enterocolitis. Pediatr Res. 2012;72:513–520.
36. Jenke AC, Postberg J, Mariel B, Hensel K, Foell D, Däbritz J, Wirth S. S100A12 and hBD2 correlate with the composition of the fecal microflora in ELBW infants and expansion of E. coli is associated with NEC. Biomed Res Int. 2013;2013:150372.
37. Wehkamp J, Harder J, Wehkamp K, et al. NF-B and AP-1-mediated induction of humans zlig-defensin-2 in intestinal epithelial cells by Escherischia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun. 2004;10:5750–5758.
38. Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat Rev Mol Cell Biol. 2014;15:19–33.
39. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14–22.
40. Ahmed N, Corey M, Forstner G, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut. 2003;52:1159–1164.
41. Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2011;140:153–161.
42. Ooi CY, Durie P. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. J Cyst Fibros. 2012;11:355–362.